Form 4: Acrivon Therapeutics CFO Rasmus Holm-Jorgensen Reports Changes in Beneficial Ownership

Rasmus Holm-Jorgensen, CFO of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Summary

• On August 14, 2024, Rasmus Holm-Jorgensen, the Chief Financial Officer of Acrivon Therapeutics, Inc., reported a change in beneficial ownership of the company's common stock.
• The transaction involved the withholding of 368 shares by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• The price per share for the transaction was $7.02.
• Following the transaction, Holm-Jorgensen directly owns 26,890 shares of Acrivon Therapeutics common stock.

Sentiment

Score: 5

Explanation: This is a routine filing related to tax obligations on vested stock units, and it doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders and their holdings in the company. This filing indicates a standard tax withholding procedure related to vested stock units.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it involves a small number of shares withheld for tax purposes.

Key Dates